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The presence of increasing host chimerism or persistent mixed chimerism (MC) after hematopoietic stem cell
transplantation for leukemia in children is a predictor of relapse. To reduce the risk of relapse, we pro-
spectively studied post-transplantation chimerism-based immunotherapy (IT) using fast withdrawal of
immunosuppression (FWI) and donor lymphocyte infusions (DLI) in children with early post-transplantation
MC. Forty-three children with hematologic malignancies at 2 institutions were enrolled prospectively in this
study from 2009 until 2012 and were followed for a mean of 42 (SD, 10) months. Twelve patients (28%) were
assigned to the observation arm based on the presence of graft-versus-host disease (GVHD) or full donor
chimerism (FDC), and 5 (12%) sustained early events and could not undergo intervention. Twenty-six (60%)
patients with MC were assigned to IT with FWI, which started at a median of 49 days (range, 35 to 85 days)
after transplantation. Fourteen patients proceeded to DLI after FWI. Toxicities of treatment included GVHD,
which developed in 19% of patients undergoing intervention, with 1 of 26 (4%) dying from GVHD and 1 (4%)
still requiring therapy for chronic GVHD 21 months after DLI. Patients with MC undergoing IT had similar 2-
year event-free survival (EFS) (73%; 95% conﬁdence interval (CI), 55% to 91%) compared with patients who
achieved FDC spontaneously (83%; 95% CI, 62% to 100%); however, because 50% of all relapses in the IT
occurred later than 2 years after transplantation, the EFS declined to 55% (95% CI, 34% to 76%) at 42 (SD, 11)
months. There were no late relapses in the observation group. EFS in the entire cohort was 58% (95% CI, 42% to
73%) at 42 (SD, 11) months after transplantation. Evidence of disease before transplantation remained a
signiﬁcant predictor of relapse, whereas development of chronic GVHD was protective against relapse.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Relapse of leukemia after hematopoietic stem cell trans-
plantation (HSCT) remains the most common cause of
transplantation failure, and few options are available for its
treatment. Data from the Center for International Blood and
Marrow Transplant Research indicate that the incidence of
relapse after transplantatiom is 30% to 35% for children with
acute lymphoblastic leukemia (ALL) [1] and 39% for children
undergoing transplantation for acute myelogenous leukemiadgments on page 737
quests: Biljana Horn, MD, Benioff Chil-
sus Avenue, Room M-659, San Francisco,
sf.edu (B. Horn).
14.12.029
ty for Blood and Marrow Transplantation.(AML) [2]. In the 1990s, with development of more sensitive
chimerism testing, the presence of residual host cells after
HSCT for leukemia was recognized as an important predictor
of relapse. Bader et al. [3] and Barrios et al. [4] showed that
the presence of an increasing amount of host cells after HSCT
for leukemia was associated with an approximately 90%
chance of relapse in children and adults. To reduce this high
relapse rate, European investigators used pre-emptive
immunotherapy (IT) consisting of fast withdrawal of immu-
nosuppression (FWI) and donor lymphocyte infusions (DLI)
in pediatric patients with documented increasing host
chimerism or persistent mixed chimerism (MC) [5-7].
In 2005, we started using chimerism-based post-trans-
plantation IT. The results of our ﬁrst multi-institutional
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Figure 1. Algorithm of study interventions.
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In that study, we validated the use of subset chimerism
testing and conﬁrmed the relationship between MC and
relapse. Patients with MC in any of peripheral blood (PB)
subsets who did not receive intervention had a 71% relapse
rate as opposed to an 11% relapse rate in patients with full
donor chimerism (FDC) [8].
This second prospective multi-institutional study was
designed to prospectively evaluate efﬁcacy and toxicity of
pre-emptive chimerism-based IT in pediatric hematologic
malignancies. We describe chimerism data, details of
immunomodulatory interventions, the incidence of graft-
versus-host disease (GVHD), the relapse rate, and risk fac-
tors for relapse.PATIENTS AND METHODS
Patients between 6 months and 25 years of age receiving a myeloa-
blative HSCT for acute leukemia (AML, ALL, biphenotypic leukemia), juvenile
myelomonocytic leukemia, or myelodysplastic syndromes were eligible for
this study. Donors and recipients were required to be HLA matched at a
minimum of 7 of 8 loci (A, B, C, DRB1), using high-resolution typing. Only
patients receiving unmodiﬁed bonemarrow (BM) or PB as a stem cell source
were included, and there was a requirement that donor cells be available foradditional DLIs. All patients and all donors provided written informed
consent. Patients were enrolled at Benioff Children’s Hospital at University
of California San Francisco and All Children’s Hospital, St. Petersburg, Florida
from 2009 until 2012. The studywas approved by the committees on human
research from both institutions as well as the National Marrow Donor Pro-
gram, and was registered with ClinicalTrials.gov as NCT01036009.
Deﬁnitions
MCwas deﬁned as the presence of 1% or more of host cells in any of the
tested subsets. To initiate FWI, MC was required on 2 different tests: either
PB and BM performed at the same time, or 2 PB or 2 BM specimens per-
formed 2 weeks apart. FDC was deﬁned as 100% donor in all tested subsets.
Assignment to Treatment Arms and Schedule of Chimerism Testing
From November 2009 until November 2010, the study required that the
ﬁrst chimerism test be done on day 30  7 after transplantation and
conﬁrmatory chimerism test be done on day 45  7, at which time PB and
BM chimerism tests were obtained. The assignment to the intervention arm
was done afterMCwas conﬁrmed on 2 subsequent tests done 2weeks apart.
The intervention consisting of fast withdrawal of calcineurin inhibitor (CNI)
started on day 60  7. The CNI was tapered over 3  1 weeks. However,
because of a number of early relapses that occurred before the patient could
be randomized to the intervention arm, in November 2010 the study was
amended to obtain chimerism from both PB and BM on day 28  7.
Conﬁrmatory chimerism was done only if there was a discrepancy between
PB and BM chimerism (eg, if PB showed 100% donor in all subsets and BM
Table 1
Characteristics of Patients and Transplantations
Characteristic n (%)
Gender
Male 23 (46.5)
Female 20 (53.5)
Type of malignancy
ALL 17 (39.5)
Induction failure* 2 (4.6)
CR1 4 (9.3)
CR2 9 (21.0)
CR3 2 (4.6)
AML 25 (58.1)
CR1 9 (21.0)
CR2, ﬁrst transplantation 6 (13.9)
CR2, second transplantation 3 (7.0)
t(AML) or AML second to MDS 4 (9.3)
JMML 2 (4.6)
MDS 1 (2.3)
Biphenotypic leukemia CR1 1 (2.3)
Evidence of disease before conditioning regimen
Negative 32 (74.4)
Positive 11 (25.6)
1%-10% blasts 8 (18.6)
>.01% < 1% blasts 3 (7.0)
Stem cell source
BM 23 (53.5)
PB 20 (46.5)
Donor type
Matched related donor 20 (46.5)
Matched unrelated donor (8/8) 13 (30.2)
Mismatched unrelated donor (7/8) 10 (23.3)
Conditioning regimens
TBI-based (12-13.5 Gy)
TBI þ Cy 14 (32.6)
TBI þ Cy þ thiotepa 4 (9.3)
Other TBI-based 1 (2.3)
Chemotherapy-based
Busulfan þ ﬂudarabine 16 (37.2)
Melphalan þ ﬂudarabine 2 (4.6)
þ Thiotepa
Other busulfan-based 6 (14.0)
Use of serotherapy during conditioning
Yes 29 (67.4)
Horse ATG 6 (14.0)
Rabbit ATG (Thymoglobulin [Genzyme, Cambridge, MA]) 21 (48.8)
Alemtuzumab 2 (4.6)
No 14 (32.6)
GVHD prophylaxis
Cyclosporine þ methotrexate 32 (74.4)
Tacrolimus þ methotrexate 6 (14.0)
Cyclosporine þ MMF 1 (2.3)
Tacrolimus þ MMF 4 (9.3)
CR1 indicates ﬁrst complete remission; CR2, second complete remission;
CR3, third complete remission; t(AML), treatment-related AML; MDS,
myelodysplastic syndrome; JMML, juvenile myelomonocytic leukemia; TBI,
total body irradiation; Cy, cyclophosphamide; ATG, antithymocyte globulin;
MMF, mycophenolate mofetil.
* Indicates >25% of at the end of ﬁrst induction.
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MC persisted, the intervention would start). Intervention with FWI started
earlier in the amended study, on day 45  7, as opposed to day 60  7. Pa-
tients who had 100% donor chimerism on all PB and BM subsets, patients
with any evidence of acute GVHD or peri-engraftment syndrome (deﬁned as
fever, rash respiratory symptoms occurring within 96 hour of engraftment
and resolving with a short course of steroids), and those who had >1%
leukemic blasts on the ﬁrst post-transplantation disease evaluation test,
were assigned to the observation arm. A subgroup of patients treated before
November 2010 who had an event (death or relapse) before randomization
occurred are presented separately as an “early event” group.
Figure 1 depicts the study intervention algorithm, as used since
November 2010. PB chimerism testing included whole blood and CD3þ
lineage in all patients and included the leukemia-speciﬁc subset deﬁned
as CD19þ lineage in patients with B lymphoid malignancies and CD14/15þ
lineage in patients with myeloid malignancies. Bone marrow evaluation
for chimerism and disease evaluation were required for all patients who
did not have evidence of acute GVHD, and was done at days 28 to 45 after
transplantation. Disease evaluation included morphology and either
multiparametric ﬂow, PCR, or cytogenetics by FISH analysis, depending on
which test was used for disease evaluation before transplantation.
Chimerism testing was done on whole BM, and whenever a sufﬁcient
specimen was available, subsets were also tested (CD34þ and CD3þ in all
patients and leukemia-speciﬁc subsets, deﬁned as CD33þ and CD14/15þ in
patients with myeloid malignancies and CD19þ in those with lymphoid
malignancies). Details of isolation of cell subsets and chimerism testing
using a semi-quantitative PCR-based method involving ampliﬁcation of
genes containing short tandem repeats were previously published [8]. As
previously described, the sensitivity of the chimerism assay was depen-
dent on the percentage of donor cells present. If the donor cells were 95%
to 99%, the assay sensitivity was 1%; for 90% to 94% donor cells, the
sensitivity was 3%; for 11% to 89% donor cells, the sensitivity of the assay
was 6% [8].
Schedule and Dose of Donor Lymphocyte Infusions
Patients were eligible for IT with DLIs if MC persisted after FWI. Four
weeks after each DLI dose, the chimerism test was repeated and if MC was
documented, the patient underwent a subsequent, larger dose of DLI. DLI
was repeated every 6 to 8 weeks until FDC in all PB subsets was documented
on 2 tests that were done 4 weeks apart. Once FDC was achieved, chimerism
was tested annually or sooner if clinically indicated.
Recommended DLI doses and schedule of DLI escalation were as fol-
lows: for mismatched related and unrelated donor transplant recipients,
the ﬁrst DLI dose was 1 105/kg of CD3þ cells, the second dose was 5  105
to 1  106/kg of CD3þ cells, the third dose was 1  106/kg to 1  107/kg of
CD3þ cells, and the fourth and subsequent doses were 1 107/kg of CD3þ
cells. For the recipients of fully matched related donor transplants, the ﬁrst
DLI dose was 1  106/kg of CD3þ cells, the second dose was 5  106 to 1 
107/kg of CD3þ cells, the third dose was 1  107/kg to 1  108/kg of CD3þ
cells, and the fourth and subsequent doses were 1  108/kg of CD3þ cells.
Whenever possible, cells for DLI were obtained with the original mobilized
PB stem cells or BM collection and cryopreserved. If sufﬁcient cells for DLI
were not available at the time of collection or if all originally collected cells
were used, unmobilized PB was obtained for DLI by blood draw or
apheresis procedure. The dose was not changed when unmobilized DLIs
were used.
The study was designed to discontinue all interventions 1 year after
transplantation; however, if FDC was not achieved by 1 year after trans-
plantation, patients could have continued DLIs off study. The study did not
require conﬁrmation of FDC in the BM at the end of intervention, except in
instances where the initial testing showed MC in BM alone, which did not
occur in any patients. If at any point during the intervention a patient
developed GVHD, IT was discontinued and treatment of GVHDwas initiated.
Acute and chronic GVHD were graded using published criteria [9,10].
Supportive care, conditioning regimens, and GVHD prophylaxis were pro-
vided as per standard of care. All patients received CNI and an additional
agent (methotrexate or mycophenolate mofetil) for GVHD prophylaxis, and
some patients received pre-HSCT serotherapy.
Statistical Analysis
Data were analyzed using SPSS v16.0 statistical program (SPSS Inc.
Chicago, IL). Descriptive statistics, including the Fisher’s exact test with 2-
sided P values for the comparison of categorical variables and 2-sided Stu-
dent’s t-test for comparison of means, were used. Event-free survival (EFS)
was calculated using Kaplan-Meier analysis from the time of transplantation
until the last contact for living patients or date of event (relapse or toxic
death). The mean survival and 95% conﬁdence interval (CI) are presented.
Log-rank test was used for comparison of distribution curves.RESULTS
Patient and Transplantation Characteristics
Table 1 outlines characteristics of 43 patients treated in
this study, including conditioning regimens, GVHD prophy-
laxis, disease status before transplantation, donor types, and
stem cell sources. Mean age at the time of transplantation
was 10.8 (SD, 6.5) years (range, 1 to 24 years). Nineteen pa-
tients (44%) had pretransplantation disease evaluation done
by multiparametric ﬂow performed at the University of
Washington, Seattle; the remaining patients had pre-
transplantation disease evaluation done by morphology,
immunoﬂow, and/or cytogenetics and FISH testing at a local
institution.
Table 2
Early Post-Transplantation Chimerism Results (% Donor) by Treatment Arm
Intervention
Arm
Observation
Arm
Early
Events Arm
PB 26 (98.1  3.0) 12 (99.6  .9) 4 (98.5  2.3)
PB CD3þ subset 26 (84.2  21.1) 12 (97.4  5.2) 4 (98.5  1.3)
PB Leukemia-
speciﬁc subset
26 (99.3  .6) 12 (99.9  .3) 4 (98.7  1.3)
BM 26 (99.0  .7) 10 (99.6  .7) 3 (88.3  9.1)
BM CD3þ subset 21 (90.9  10.4) 6 (98.0  4.4) 2 (97  1.4)
BM CD34þ 22 (98.7  1.9) 7 (99.1  1.2) 2 (53  59)
BM Leukemia-
speciﬁc subset
23 (99.1  1.5) 8 (99.7  .5) 2 (93  2.8)
Data presented are n (mean SD), % donor. Number of patients who had the
test done (because of low counts, not all subsets could have been obtained
on each testing).
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Evaluation, and Assignment to Treatment Arms
Early post-transplantation chimerism tests, used for
decision-making for assignment to the intervention arm,
were obtained from PB on post-transplantation day 32.5 (SD,
8.8) and BM on day 37.9 (SD, 9.9). Table 2 summarizes results
of early post-transplantation chimerism tests and shows
overall very high levels of donor chimerism.
Patients with Early Post-Transplantation Events
Five patients could not be assigned to either observation
or intervention arm because of early events. One patient
who had treatment-related AML (-7q) did not engraft and
had evidence of AML progression on the ﬁrst post-
transplantation BM exam. Three patients who were
engrafted with donors’ cells had >1% leukemic blasts by
multiparametric ﬂow on the ﬁrst post-transplantation BM
evaluation and were not eligible for pre-emptive IT. One
patient died 2 months after transplantation, without evi-
dence of disease, because of liver dysfunction. No patients in
this group achieved FDC. After the protocol wasmodiﬁed and
conﬁrmatory testing at day þ45 was eliminated, no addi-
tional events before randomization were encountered.
Observation Arm Outcomes
Twelve patients (28%) were assigned to the observation
arm: 7 (58%) because of the presence of acute GVHD, 2 (17%)
because of peri-engraftment syndrome, and 3 (25%) because
of FDC in all tested subsets and no evidence of GVHD. Only 4
of 9 (44%) patients who had GVHD or peri-engraftment
syndrome had FDC in all tested subsets on the early post-
transplantation testing. All surviving patients in theTable 3
Summary of Outcomes by Treatment Arm and Early Post-Transplantation Chimeri
Outcome Early Events
Arm
Intervent
Arm
Relapse rate 4 of 5 (80%) 8 of 26 (3
Toxic death 1 of 5 (20%) 1 of 26 (4
Secondary malignancy 0 1 of 26 (4
aGVHD (all grades) 1 of 5 (20%) 3 of 26 (1
aGVHD (grade III-IV) 0 1 of 26 (4
cGVHD n/a 3 of 26 (1
Patients with aGVHD and/or cGVHD, any grade 1 of 5 (20%) 5 of 26 (1
2-Year EFS 0 73% (9
EFS at a mean f/u of 42  10 months 0 55% (9
aGVHD indicates acute graft-versus-host-disease; cGVHD, chronic graft-versus-ho
Data presented are n (%) unless otherwise indicated.observation group achieved FDC in PB in all subsets at a
median of 48 days after transplantation (range, 21 to 355).
Two patients in the observation group died because of
relapse, which occurred at 4 months after transplantation in
both patients. One of them had evidence of grade 2 acute
GVHD andMC; the other patient, for whom this was a second
transplantation for monosomy 7, had no GVHD and had FDC
on the initial post-transplantation test (although BM subsets
could not be tested). Grade II to IV acute GVHDwas present in
7 of 12 patients (58%); however, only 3 of 12 (25%) patients
had GVHD of grade III or higher. Chronic extensive GVHDwas
present in 6 of 12 (50%) patients in this group, and 3 of them
are still on therapy at 45, 46, and 60 months after
transplantation.
Table 3 summarizes relapse rate, GVHD rates, 2-year EFS,
and EFS at the mean study follow-up (42 months) by treat-
ment arm and by chimerism status.Intervention ArmdFWI and DLI
Table 4 presents the details of intervention including time
to FWI, time and number of DLIs, chimerism, GVHD, and
outcomes. Twenty-six patients (60%) underwent FWI and 14
(33%) underwent subsequent DLIs. Median time to initiation
of FWI was day 49 (range, 35 to 85), and median time to
discontinuation of CNI was day 75 (range, 49 to 113). After
FWI, 3 of 26 (11.5%) patients developed acute GVHD of grades
I, II, and IV. The patient with grade IV GVHD (patient 25UC)
progressed to severe chronic lung GVHD and died from
fungal infection 7 months after transplantation.
The median time to ﬁrst DLI was 118 days (range, 85 to
194) and the median time to the last DLI was 223 days
(range, 85 to 627). Three patients received 1 DLI only, 3
received 2 DLIs, 4 received 4 DLIs, and 1 patient each
received 5, 6, 7, and 8 DLIs. Cumulative DLI dose in millions
of CD3þ cells/kg of recipient’s weight is presented in Table 4
and ranged between .1 and 166. Only 2 patients have
received DLIs from mismatched unrelated donors. There
were no episodes of acute GVHD after DLI infusions, and
only 2 of 14 (14%) patients developed chronic extensive
GVHD after DLI infusions, 1 of whom remains on therapy 21
months after DLI. Relapse occurred in 8 of 26 (30.7%) pa-
tients, and 4 out of these 8 relapses (50%) occurred later
than 2 years after transplantation. Three of these late re-
lapses were in patients with myeloid malignancies and 1
was in a patient with ALL. Of 4 patients with late relapses, 2
received FWI only and 2 received DLIs; none developed
GVHD. Patient 05UC received 8 DLIs from a mismatched
unrelated donor with a cumulative DLI dose of 14  106sm
ion All Patients with
MC (Early Events þ
Intervention Arms)
Observation Arm/FDC
0.8%) 12 of 31 (39%) 2 of 12 (17%)
%) 2 of 31 (6%) 0 of 12 (0%)
%) 1 of 31 (3%) 0 of 12 (0%)
1.5%) 4 of 31 (13%) 7 of 12 (58%)
%) 1 of 31 (3%) 3 of 12 (25%)
1.5%) 3 of 26 (11.5%) 6 of 12 (50%)
9.2%) 6 of 31 (19%) 8 of 12 (67%)
5% CI, 55-91) 61% (95% CI, 43-79) 83%, (95% CI, 63-100)
5% CI, 34-76) 46%, (95% CI 27-65) 83%, (95% CI, 63-100)
st-disease; n/a, not available; f/u, follow-up.
Table 4
Details of Intervention
ID Malignancy
Type
Stem Cell
Source
Donor
Match
Start
of FWI*
End
of FWI*
Chimerism
after FWI
First DLI
Given*
Last DLI
Given*
Number
of DLIs
DLI Dosey Time FDC
Achieved, d
aGVHD, Grade
and Timing
cGVHD, Grade
and Timing
Outcome EFS
37SP Lymphoid BM Genotypic 39 62 FDC 91 No No Alive and well 32
09SP Lymphoid PB Genotypic 50 75 MC 735z I after FWI No Alive and well 53
38UC Lymphoid BM MUD 52 80 FDC 83 No No Alive and well 31
16UC Myeloid PB Genotypic 53 70 FDC 105 No No Late relapse, death 31
25UC Myeloid PB MMUD 48 82 FDC 82 IV after FWI Severe
lung cGVHD
Death due to GVHD 7
39UC Lymphoid PB MUD 54 62 FDC 96 no no Alive and well,
MC recurred at 16 mo after
transplantation
33
22SP Myeloid BM Genotypic 56 76 n/a Not tested II after FWI No Relapse, death 8
15SP Lymphoid BM MUD 61 82 FDC 120 No No Late relapse, death 36
27UC Myeloid PB Genotypic 70 90 MC 208 No No Alive and well FDC 42
36UC Lymphoid BM Genotypic 80 111 MC Not achieved No No Relapse, death 4
11UC Lymphoid PB Genotypic 40 49 MC Not achieved No No Relapse, death 2
01UC Lymphoid BM MUD 85 113 FDC 141 No No Alive and well 60
42UC Myeloid BM Genotypic 39 74 MC 118 349 6 166 370 No No Alive and well 30
44UC Lymphoid PB Genotypic 35 56 MC 95 223 4 66 267 No Ext cGVHD,
after DLI
Alive, on GVHD tx 28
17UC Myeloid BM Genotypic 40 56 MC 113 158 2 6 237 No No Late relapse, death after second
transplantation due to disease
25
32UC Myeloid PB Genotypic 40 68 MC 120 266 4 26 340 No No Alive and well 40
05UC Myeloid BM MUD 45 60 MC 137 627 8 14.1 Not achieved No No Late relapse, death after second
transplantation due to toxicities
36
37UC Myeloid PB MUD 47 96 MC 194 404 4 5.6 467 No No Alive and well 33
20SP Lymphoid PB MMUD 47 77 MC 99 n/a 1 .1 168 No No Alive and well 46
30UC Myeloid PB MUD 48 76 MC 129 207 2 .6 Not achieved No No Relapse, death 8
12UC Lymphoid BM Genotypic 48 82 MC 134 n/a 1 1 167 No No Alive and well 52
33SP Myeloid BM Genotypic 50 71 MC 85 n/a 1 1 243 No No Alive and well 31
41UC Lymphoid BM MUD 50 77 MC 137 212 2 .6 248 No No Alive and well 30
40UC Lymphoid PB MMUD 52 73 MC 116 269 5 71.1 Not achieved No No second malignancy (MDS),
alive 20 mo after
second transplantation
10
08UC Myeloid BM Genotypic 56 91 MC 145 574 7 92 977 No Ext cGVHD,
after DLI
Alive, off GVHD tx 54
26UC Myeloid BM MUD 61 80 MC 106 259 4 51 433 No No Alive and well 43
MUD indicates matched unrelated donor; MMUD, mismatched unrelated donor; MDS, myelodysplastic syndrome; Ext cGVHD, extensive chronic graft-versus-host disease; tx, treatment.
* Days after transplantation.
y DLI dose in millions.
z Chimerism not tested earlier as patient had GVHD.
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Figure 2. Event-free-survival by early post-transplantation chimerism status.
B. Horn et al. / Biol Blood Marrow Transplant 21 (2015) 729e737734CD3þ/kg; however, he never achieved FDC and his juvenile
myelomonocytic leukemia relapsed 36 months after trans-
plantation. Patient 17UC received a cumulative DLI dose of
6  106 CD3þ cells/kg from a matched related donor,
developed FDC without evidence of GVHD, and relapsed 25
months after transplantation. Only 1 of 26 (3.8%) patients
(11UC) had documented evidence of minimum residual
disease (MRD) early after transplantation by multi-
parametric ﬂow at a very low level (.005%). Despite
discontinuation of immunosuppression over 1 week, leu-
kemia promptly relapsed and the patient died.
Chimerism after intervention
Three patients in the intervention arm required contin-
uation of DLIs past 1 year after transplantation; 2 of them
achieved FDC at 467 and 977 days after transplantation. One
patient (05UC) did not achieve FDC despite 8 DLIs and sus-
tained late relapse. All surviving patients in the intervention
arm (16 of 26) have achieved FDC in all subsets. One patient
with T cell ALL (39UC) developed 1% host cells in CD3þ
lineage at 16 months after transplantation after having pre-
viously achieved FDC. She has not received additional DLIs
because of a history of autoimmune hemolytic anemia
requiring steroids. Her MRD is followed by high throughput
sequencing and has remained negative.Figure 3. Relapse rate by early post-trOutcomes for the Entire Cohort
Themean follow-upof livingpatients is 42 (SD,10)months
with a range of 28 to60months. TheKaplan-Meierestimateof
EFS in all 43 patients enrolled in this study was 58% (95% CI,
42% to 74%), with 14 of 43 (33%) patients sustaining relapse, 2
(4.6%) dying from toxic death, and 1 (2.3%) developing a sec-
ondary myelodysplastic syndrome, after transplantation for
ALL. Figures 2 and 3 depict EFS and relapse rates based on
early post-transplantation chimerism and intent to treat
(intervention arm þ early events versus observation arm).
After intervention, patientswithMCdidnothave signiﬁcantly
different EFS or relapse rates compared with those who ach-
ieved FDC spontaneously (log rank P for EFS, .06; for relapse
rate, P¼ .12). Late relapses were seen only in the intervention
arm. Therewere no differences in EFS between lymphoid and
myeloid malignancies (log-rank P ¼ .68).Predictors of Relapse
Figure 4 depicts EFS by pretransplantation disease status.
Overall, 7 of 11 (63%) patients with positive disease before
transplantation relapsed compared with 7 of 32 (22%) pa-
tients with negative pretransplantation disease (2-sided
Fisher exact, P ¼ .02). In the intervention arm, 4 of 5 (80%)
patients with positive disease before transplantation
relapsed, compared with 4 of 21 (19%) patients without
pretransplantation evidence of disease (2-sided Fisher exact,
P ¼ .02).
None of the 9 patients with chronic GVHD relapsed,
compared with 14 of 34 (42%) patients without chronic
GVHD (2-tailed Fisher’s exact P ¼ .02). Three of 11 (27%)
patients with acute GVHD (all of whom had GVHD grade II or
less) relapsed, compared with 11 of 32 (34%) patients
without acute GVHD (P ¼ .48). Twenty-nine patients who
underwent transplantation after the interventionwasmoved
to an earlier time-point had mean EFS of 66% as opposed to
an EFS of 50% in the 14 patients receiving intervention later
after transplantation. This was not signiﬁcantly different (log
rank P ¼ .53).
Early post-transplantation chimerism as a predictor of
relapse
Table 5 describes relapse rates and early post-
transplantation BM and PB chimerism results. As seen inansplantation chimerism status.
Figure 4. Event-free survival by pretransplantation disease status.
B. Horn et al. / Biol Blood Marrow Transplant 21 (2015) 729e737 735the table, in patients treated with pre-emptive IT approach,
only MC in BM leukemia-speciﬁc lineage remained predic-
tive of relapse.
DISCUSSION
Our prospective study of chimerism-based IT indicates
that FWI and DLI resulted in acceptable toxicities (GVHD
developed in 19% of patients and toxic death due to GVHD in
4%). Theuse of ITallowedpatients in the interventiongroup to
achieve EFS rates similar to those achieved by patients with
early acute GVHD and/or full donor chimerism. However, re-
lapses occurring later than 2 years after transplantationwere
seen only in the intervention arm, suggesting that the allor-
eactive effect of IT was waning over time. Patients with evi-
dence of disease before transplantation remained at an
increased risk of relapse, despite the intervention. As ex-
pected, chronic GVHD was protective against relapse. The
relapse rate in our entire cohort remained high (33%), likely
due to underestimateddiseaseburden, as only44%of patients
had pretransplantation disease evaluation done by multi-
parametric ﬂowand to inclusion of high-risk patients, such as
those undergoing second transplantation or having
treatment-related AML.
Detection of MC is not equivalent to detection of residual
disease, as early post-transplantation MC is causedTable 5
Relapse Rates and Early Post-Transplantation Peripheral Blood and Bone Marrow C
Chimerism n* MC
n with MC Relapse Rate
Patients with
Whole BM 39 26 38%
BM CD3 subset 29 24 30%
BM leukemia-speciﬁc subset 33 17 41%
BM CD34 subset 31 21 38%
All BM subsets 37 30 37%
Whole PB 42 22 36%
PB CD3 subset 42 31 35%
PB leukemia-speciﬁc subset 42 19 32%
All PB subsets 43 35 37%
Bold indicates statistical signiﬁcance.
* Includes number of patients tested for the speciﬁc subset.predominantly by normal recipient hematopoietic cells [11].
Persistence of host cells may reduce the clinical graft-versus-
leukemia effect by inducing tolerance [11]. In animal studies,
host antigen-presenting cells in mixed chimeras allow for
improved presentation of host antigens to donor lympho-
cytes, leading to superior alloreactivation of the intolerant
donor lymphocytes [12].
Early studies showed that childrenwith AML (n¼ 15) and
ALL (n ¼ 31) who received pre-emptive IT for increasing host
chimerism after HSCT had 36% and 37% long-term survival,
respectively, whereas there were no survivors among chil-
dren with increasing host chimerism who did not receive
pre-emptive IT [5,6]. The three-year EFS rate for the entire
cohort of children included in pre-emptive IT approach be-
tween 1996 and 2001 was 52% for AML [5], and 54% for ALL
[6], respectively. In a subsequent study conducted between
2005 and 2009, Rettinger et al. started intervention based on
presence of MC rather than increasing host chimerism [7]
and EFS increased to 46% in the IT group, compared with
36% in the previous study [6,7]. EFS for the entire cohort of
patients also improved to 66% (95% CI, 53% to 76%) from 52%
in the previous study [6,7].
In 2005, we conducted the ﬁrst United States pediatric
multi-institutional feasibility study of chimerism-based IT
and indicated that MC should be used as the basis forhimerism
FDC
in
MC
n with FDC Relapse Rate in
Patients with FDC
P Value
(Fisher’s Exact)
13 15% .30
5 0% .30
16 6% .04
10 10% .20
7 0% .08
20 25% .50
11 18% .50
23 30% 1.00
8 12% .20
B. Horn et al. / Biol Blood Marrow Transplant 21 (2015) 729e737736post-transplantation IT, as waiting for documentation of
increasing host chimerism delayed intervention and resulted
in increased risk of relapse [8]. The study also described the
importance of achieving FDC in all PB cell lineages, as pa-
tients with FDC in all subsets had an 11% relapse rate
compared with a 71% relapse rate in patients with MC in any
of the PB subsets who did not undergo intervention [8].
When compared to historic control fromour feasibility study,
which had the same inclusion criteria, the relapse rate in
patients withMCwhowere eligible for intervention declined
from 71% to 39% (2-tailed Fisher’s exact, P ¼ .20).
There are a number of differences between the European
approach to chimerism-based IT, most recently published in
Rettinger’s study, and our approach [7]. We tested chimerism
less frequently and did not include patients who received T
celledepleted grafts. We used gradual (over 3 to 4 weeks)
withdrawal of CNI as opposed to abruptly stopping CNI. We
used subset chimerism testing of PB and continued inter-
vention until 100% rather than 99% donor chimerism was
conﬁrmed in all subsets. Finally, we excluded from IT
patients with any acute GVHD grade or peri-engraftment
syndrome. Based on our deﬁnition of mixed chimerism, a
higher number of patients were eligible for IT and a larger
proportion of patients received pre-emptive IT than in the
European study (60% versus 18%) [7]. It is likely that some of
the patients who underwent IT in our study would have
spontaneously achieved FDC if we had waited longer. How-
ever, the toxicities of our treatment were acceptable, and
prevention of relapse was a priority as there were no long-
term survivors among patients who relapsed in our study.
Twelve percent of patients relapsed or had an event before
randomization occurred. Other studies using the pre-
emptive IT approach describe that 7% to 15% of patients
eligible for pre-emptive IT did not receive it for various
reasons, and all ultimately relapsed and died [5-7]. Earlier
start of IT (before day 45), as done in our study since
November 2010, reduced the number of children who are
ineligible for IT because of early events.
The IT did not reduce the risk of relapse in a group of
patients with pretransplantation disease, 63% of whom
relapsed. A recent Children’s Oncology Group study of pe-
diatric ALL indicated a 60% relapse rate in childrenwho were
documented to have .1% leukemia cells before trans-
plantation and who did not receive any post-transplantation
pre-emptive therapy [13]. Balduzzi et al. reported a 62%
relapse rate in children with ALL with documented pre-
transplantation MRD of 104 [14]. In that study, patients
with positive MRD before transplantation were eligible for
FWI but not DLI. DLIs were given to 7 patients with post-
transplantation evidence of MRD or increasing host chime-
rism. The DLI dose was 1  106/kg in matched related
transplantations and 5  105/kg in matched unrelated donor
transplantations. Only 1 of 7 (14%) patients is a long-term
survivor [14]. Lankester et al. pioneered preemptive FWI
and DLI in 18 children with ALL, based on pretransplantation
MRD detected by PCR at a level of 1  104 [15]. Unfortu-
nately, the relapse rate in this high-MRD group was 70%,
despite pre-emptive IT. The starting DLI dose in that study
was 1  106/kg for matched related and unrelated T
cellereplete transplantations [15].
However, a few recent reports indicate that higher DLI
doses than those used by European investigators and in our
study may be able to overcome post-transplantation MRD.
Investigators from China recently described the efﬁcacy of a
pre-emptive IT approach after documenting MRD aftertransplantation [16,17]. Yan et al. used DLI concomitantly
with chemotherapy and gave 1 to 2 log higher doses than
were used in our study [17]. Long-term survival of 56 pa-
tients with post-transplantationepositive MRDwasw40% in
that study [17]. Rujkiyanont et al. used 1 log higher DLI doses
than described in our study. In 3 of 7 (43%) children, the BM
MRD, which was positive after transplantation by multipa-
rameter ﬂow cytometry, reverted to negative and remained
negative [18]. It is possible that higher DLI doses given for
MRD may achieve better leukemia control; however, the
long-term outcomes of pre-emptive IT in patients with small
amounts of disease require further study.
Finally, we encountered a number of late relapses in pa-
tients receiving immunologic intervention who did not
develop chronic GVHD, which indicates a reduction in
alloreactive responses over time. None of the patients with
chronic GVHD sustained a relapse. Late relapses in patients
receiving IT have been previously described only by
Lankester et al. [15]. In his study of pre-emptive IT given to
patients with positive MRD before transplantation, 27% of
relapses occurred later than 1 year after transplantation and
20% of relapses occurred more than 2 years after trans-
plantation [16]. Our patients had a lower GVHD rate than
typically described in studies of pre-emptive IT, some of
which report GVHD incidence as high as 70% [19]. Although
chronic GVHD is protective against relapse, our goal was to
avoid it, given associated morbidities. Since identifying the
risk of late relapse, we have changed our practice and are
following patients with FDC but without chronic GVHD for a
minimum of 3 years after transplantation. We are now con-
ﬁrming FDC in BM, in particular in CD34þ and leukemia-
speciﬁc lineage, and evaluating MRD by the most sensitive
available technique at the end of pre-emptive IT intervention
[20,21]. Readily available strategies to enhance IT and pre-
vent relapse without increasing the risk of GVHD include
concomitant use of DLI with immunosuppression or with
immunomodulatory agents, such as azacitidine [22-26]. Also,
a number of new immunologically based approaches for
reduction of pre- or post-transplantation MRD, such as
chimeric antigen receptor T cells, bispeciﬁc T cell engagers,
and advanced conjugated immunotoxins (eg, mox-
etumomab) are being actively studied [27,28].
Since the initiation of our study, more sensitive tech-
niques, such as immunoglobulin and T cell receptor gene
high-throughput sequencing, have been introduced for
the follow-up of pre- and post-transplantation MRD for
patients with ALL [29,30]. Additional studies are still
required to better deﬁne the MRD cut-offs and establish
positive and negative predictive values for different testing
time points. Recent comparison between chimerism testing
and qPCR detection of MRD after transplantation indicated
that clone-speciﬁc quantitative polymerase chain reaction
(qPCR) was signiﬁcantly more speciﬁc and sensitive in pre-
dicting relapse than the ﬁnding of increasing host chimerism
[31]. The MRD relapse was detected by qPCR an average of
173 days before detection of hematologic relapse [31].
CONCLUSION
Our prospective study of chimerism-based IT indicates
that FWI and DLI resulted in acceptable toxicities (GVHD
developed in 19% of patients and toxic death due to GVHD in
4%). The use of IT allowed patients with early post-
transplantation MC to achieve similar survival rates as pa-
tients who achieved FDC spontaneously. Relapses occurring
later than 2 years after transplantation were seen only in
B. Horn et al. / Biol Blood Marrow Transplant 21 (2015) 729e737 737patients receiving post-transplantation IT, suggesting that
the alloreactive effect of adoptive IT wanes over time. Pa-
tients with evidence of disease before transplantation
remained at an increased risk of relapse despite IT. These
patients likely require more potent IT to overcome larger
disease burden or better methods of reducing disease burden
before HSCT. Despite IT, early BM mixed chimerism in
leukemia-speciﬁc lineage remained predictive of relapse.
Going forward, chimerism will likely not be used as the sole
basis for prediction of relapse as it is less sensitive and spe-
ciﬁc than PCR-based MRD tests; however, it may still be
useful as a marker of tolerance and potential for a potent
alloreactive response. This study provided valuable data
regarding the optimal timing and speed of FWI, timing and
dose of DLIs, and duration of follow-up after IT. These data
should be applicable to future studies of post-transplantation
IT regardless of what testingmethod is used to detectMRD or
the type of immunotherapy.ACKNOWLEDGMENTS
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